Practice question

Answer the question and get instant feedback.

Moderate"ADA 2025 supports GLP‑1 RA with proven CV benefit in T2D with ASCVD; may also reduce albuminuria; complements SGLT2i + ACEi. Others are inferior/harmful."Endocrinology"moderate"

A 59-year-old with T2D, CKD (UACR 220) and ASCVD on ACEi and SGLT2i asks about additional CV-renal protection. Which option has evidence for HF/CV benefit and may reduce albuminuria?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.